FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891566777> ?p ?o ?g. }

• W2891566777 endingPage "9524" @default.
• W2891566777 startingPage "9524" @default.
• W2891566777 abstract "9524 Background: In the phase III CheckMate 037 study, NIVO improved the objective response rate and progression-free survival with less toxicity vs chemotherapy in patients (pts) with MEL who progressed after prior IPI treatment. We report the first efficacy and updated safety data from pts with MEL in CheckMate 172, including those with rare melanoma subtypes (uveal, mucosal), brain metastases, or an ECOG performance status (PS) of 2. Methods: In this ongoing phase II, single-arm, open-label, multicenter study, pts with MEL who progressed on or after IPI were treated with NIVO 3 mg/kg Q2W for up to 2 years until progression or unacceptable toxicity (NCT02156804). We report efficacy and updated safety data from 734 treated pts with ≥1 year of follow-up (database lock: November 2016). Results: Of 734 pts, 50% had LDH>ULN, 7% ECOG PS 2, 66% M1c disease, 15% a history of brain metastases, and 23% received ≥3 prior therapies. Overall, 593 pts (81%) received more than 4 doses of NIVO. Overall, response rate at 12 weeks was 32%, with a complete response in 1% (Table). The 1-year overall survival (OS) rate was 63%. Any grade and grade 3/4 treatment-related adverse events (AEs) occurred in 66% and 17% of pts, respectively. Discontinuations due to treatment-related AEs occurred in 4% of pts. The most common treatment-related select (potentially immune-related) AEs were diarrhea (12%), hypothyroidism (9%), and pruritus (7%). Conclusions: CheckMate 172 is the largest study of NIVO efficacy and safety in pts with MEL who progressed on or after IPI. NIVO demonstrated a safety profile consistent with that of prior clinical trials. Efficacy outcomes were encouraging in some difficult-to-treat subgroups of pts with poor prognostic factors, such as mucosal melanoma and brain metastases. Clinical trial information: NCT02156804. [Table: see text]" @default.
• W2891566777 created "2018-09-27" @default.
• W2891566777 creator A5001548963 @default.
• W2891566777 creator A5012502212 @default.
• W2891566777 creator A5013384569 @default.
• W2891566777 creator A5016161312 @default.
• W2891566777 creator A5016913535 @default.
• W2891566777 creator A5017136846 @default.
• W2891566777 creator A5029398339 @default.
• W2891566777 creator A5034365278 @default.
• W2891566777 creator A5037399273 @default.
• W2891566777 creator A5053108880 @default.
• W2891566777 creator A5058294413 @default.
• W2891566777 creator A5060207140 @default.
• W2891566777 creator A5062578923 @default.
• W2891566777 creator A5069095893 @default.
• W2891566777 creator A5071850607 @default.
• W2891566777 creator A5085499539 @default.
• W2891566777 creator A5087842420 @default.
• W2891566777 creator A5089297467 @default.
• W2891566777 creator A5090633646 @default.
• W2891566777 date "2017-05-20" @default.
• W2891566777 modified "2023-10-18" @default.
• W2891566777 title "Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172)." @default.
• W2891566777 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.9524" @default.
• W2891566777 hasPublicationYear "2017" @default.
• W2891566777 type Work @default.
• W2891566777 sameAs 2891566777 @default.
• W2891566777 citedByCount "15" @default.
• W2891566777 countsByYear W28915667772017 @default.
• W2891566777 countsByYear W28915667772018 @default.
• W2891566777 countsByYear W28915667772019 @default.
• W2891566777 countsByYear W28915667772020 @default.
• W2891566777 countsByYear W28915667772021 @default.
• W2891566777 countsByYear W28915667772023 @default.
• W2891566777 crossrefType "journal-article" @default.
• W2891566777 hasAuthorship W2891566777A5001548963 @default.
• W2891566777 hasAuthorship W2891566777A5012502212 @default.
• W2891566777 hasAuthorship W2891566777A5013384569 @default.
• W2891566777 hasAuthorship W2891566777A5016161312 @default.
• W2891566777 hasAuthorship W2891566777A5016913535 @default.
• W2891566777 hasAuthorship W2891566777A5017136846 @default.
• W2891566777 hasAuthorship W2891566777A5029398339 @default.
• W2891566777 hasAuthorship W2891566777A5034365278 @default.
• W2891566777 hasAuthorship W2891566777A5037399273 @default.
• W2891566777 hasAuthorship W2891566777A5053108880 @default.
• W2891566777 hasAuthorship W2891566777A5058294413 @default.
• W2891566777 hasAuthorship W2891566777A5060207140 @default.
• W2891566777 hasAuthorship W2891566777A5062578923 @default.
• W2891566777 hasAuthorship W2891566777A5069095893 @default.
• W2891566777 hasAuthorship W2891566777A5071850607 @default.
• W2891566777 hasAuthorship W2891566777A5085499539 @default.
• W2891566777 hasAuthorship W2891566777A5087842420 @default.
• W2891566777 hasAuthorship W2891566777A5089297467 @default.
• W2891566777 hasAuthorship W2891566777A5090633646 @default.
• W2891566777 hasConcept C121608353 @default.
• W2891566777 hasConcept C126322002 @default.
• W2891566777 hasConcept C141071460 @default.
• W2891566777 hasConcept C143998085 @default.
• W2891566777 hasConcept C197934379 @default.
• W2891566777 hasConcept C2775832928 @default.
• W2891566777 hasConcept C2777701055 @default.
• W2891566777 hasConcept C2779802037 @default.
• W2891566777 hasConcept C2780030458 @default.
• W2891566777 hasConcept C2781433595 @default.
• W2891566777 hasConcept C29730261 @default.
• W2891566777 hasConcept C31760486 @default.
• W2891566777 hasConcept C71924100 @default.
• W2891566777 hasConcept C90924648 @default.
• W2891566777 hasConceptScore W2891566777C121608353 @default.
• W2891566777 hasConceptScore W2891566777C126322002 @default.
• W2891566777 hasConceptScore W2891566777C141071460 @default.
• W2891566777 hasConceptScore W2891566777C143998085 @default.
• W2891566777 hasConceptScore W2891566777C197934379 @default.
• W2891566777 hasConceptScore W2891566777C2775832928 @default.
• W2891566777 hasConceptScore W2891566777C2777701055 @default.
• W2891566777 hasConceptScore W2891566777C2779802037 @default.
• W2891566777 hasConceptScore W2891566777C2780030458 @default.
• W2891566777 hasConceptScore W2891566777C2781433595 @default.
• W2891566777 hasConceptScore W2891566777C29730261 @default.
• W2891566777 hasConceptScore W2891566777C31760486 @default.
• W2891566777 hasConceptScore W2891566777C71924100 @default.
• W2891566777 hasConceptScore W2891566777C90924648 @default.
• W2891566777 hasIssue "15_suppl" @default.
• W2891566777 hasLocation W28915667771 @default.
• W2891566777 hasOpenAccess W2891566777 @default.
• W2891566777 hasPrimaryLocation W28915667771 @default.
• W2891566777 hasRelatedWork W2891745547 @default.
• W2891566777 hasRelatedWork W2899127460 @default.
• W2891566777 hasRelatedWork W2947988614 @default.
• W2891566777 hasRelatedWork W2983304924 @default.
• W2891566777 hasRelatedWork W3005150264 @default.
• W2891566777 hasRelatedWork W3016822790 @default.
• W2891566777 hasRelatedWork W3174164643 @default.
• W2891566777 hasRelatedWork W3175085288 @default.
• W2891566777 hasRelatedWork W4206770832 @default.
• W2891566777 hasRelatedWork W4308384320 @default.
• W2891566777 hasVolume "35" @default.

• next